UroGen Pharma Files 8-K for Operations and Financials
Ticker: URGN · Form: 8-K · Filed: 2024-05-13T00:00:00.000Z
Sentiment: neutral
Topics: 8-K, financial-reporting
TL;DR
UroGen Pharma filed its 8-K. Standard financial and operational update.
AI Summary
UroGen Pharma Ltd. filed an 8-K on May 13, 2024, to report on its results of operations and financial condition, as well as to file financial statements and exhibits. The filing does not contain specific financial figures or operational details in the provided text, but indicates a standard reporting event for the company.
Why It Matters
This filing is a routine disclosure for UroGen Pharma, providing updates on its financial performance and operational status to investors and the SEC.
Risk Assessment
Risk Level: low — This is a routine filing that does not appear to contain any new material information or significant events.
Key Players & Entities
- UroGen Pharma Ltd. (company) — Registrant
- May 13, 2024 (date) — Filing Date
FAQ
What specific financial results are being reported in this 8-K?
The provided text indicates the filing is for 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits', but does not detail the specific financial figures within this excerpt.
What is the exact date of the earliest event reported in this filing?
The earliest event reported is dated May 13, 2024.
What is UroGen Pharma Ltd.'s principal executive office address?
The address of the principal executive offices is 400 Alexander Park Drive, 4th Floor Princeton, New Jersey 08540.
What is the company's telephone number?
The company's telephone number, including area code, is +1 (646) 768-9780.
What is the SIC code for UroGen Pharma Ltd.?
The Standard Industrial Classification (SIC) code for UroGen Pharma Ltd. is PHARMACEUTICAL PREPARATIONS [2834].
Filing Stats: 498 words · 2 min read · ~2 pages · Grade level 11.2 · Accepted 2024-05-13 08:01:33
Filing Documents
- d804276d8k.htm (8-K) — 25KB
- d804276dex991.htm (EX-99.1) — 65KB
- 0001193125-24-136728.txt ( ) — 223KB
- urgn-20240513.xsd (EX-101.SCH) — 3KB
- urgn-20240513_lab.xml (EX-101.LAB) — 18KB
- urgn-20240513_pre.xml (EX-101.PRE) — 11KB
- d804276d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibit Number Description 99.1 Press Release dated May 13, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: May 13, 2024 UROGEN PHARMA LTD. By: /s/ Don Kim Don Kim Chief Financial Officer